Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Ripretinib

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Completed2
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04633122Phase 2CompletedPrimary

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

NCT05354388UnknownPrimary

Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observational Study

NCT03440515Phase 2CompletedPrimary

Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor

Showing all 3 trials

Research Network

Common Treatments

  • Ripretinib1
  • Prednisone1
  • Resection Surgery Of Gastrointestinal Stromal Tumor1
  • Sunitinib1

Active Sponsors

  • Sichuan Provincial People's Hospital1
  • Zai Lab (Shanghai) Co., Ltd.1
  • Asan Medical Center1

Top Investigators

Activity Timeline